Atlantic Union Bankshares Corp grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 22.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,407 shares of the medical instruments supplier’s stock after acquiring an additional 5,311 shares during the quarter. Atlantic Union Bankshares Corp’s holdings in Becton, Dickinson and were worth $6,842,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. FMR LLC increased its holdings in Becton, Dickinson and by 35.7% in the 2nd quarter. FMR LLC now owns 12,360,686 shares of the medical instruments supplier’s stock worth $2,957,540,000 after buying an additional 3,253,254 shares during the period. BlackRock Inc. increased its holdings in Becton, Dickinson and by 9.2% in the 2nd quarter. BlackRock Inc. now owns 20,760,348 shares of the medical instruments supplier’s stock worth $4,967,327,000 after buying an additional 1,755,896 shares during the period. Vanguard Group Inc. increased its holdings in Becton, Dickinson and by 4.4% in the 2nd quarter. Vanguard Group Inc. now owns 25,098,916 shares of the medical instruments supplier’s stock worth $6,005,418,000 after buying an additional 1,059,636 shares during the period. Clearbridge Investments LLC increased its holdings in Becton, Dickinson and by 233.2% in the 1st quarter. Clearbridge Investments LLC now owns 1,443,571 shares of the medical instruments supplier’s stock worth $331,689,000 after buying an additional 1,010,279 shares during the period. Finally, Two Sigma Advisers LP increased its holdings in Becton, Dickinson and by 1,089.1% in the 2nd quarter. Two Sigma Advisers LP now owns 354,075 shares of the medical instruments supplier’s stock worth $84,720,000 after buying an additional 324,298 shares during the period. Hedge funds and other institutional investors own 84.18% of the company’s stock.
Shares of NYSE:BDX traded up $1.98 during midday trading on Friday, reaching $236.99. 1,055,055 shares of the company’s stock traded hands, compared to its average volume of 1,931,858. Becton, Dickinson and Company has a 1 year low of $197.75 and a 1 year high of $286.72. The company has a market cap of $68.70 billion, a P/E ratio of 85.25, a PEG ratio of 2.36 and a beta of 0.84. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.97 and a current ratio of 1.45. The company has a fifty day simple moving average of $233.68 and a two-hundred day simple moving average of $247.53.
Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.04 by $0.16. Becton, Dickinson and had a return on equity of 14.19% and a net margin of 5.30%. The firm had revenue of $3.86 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter last year, the firm posted $3.08 EPS. The business’s revenue was down 11.4% on a year-over-year basis. As a group, research analysts forecast that Becton, Dickinson and Company will post 9.9 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Tuesday, September 8th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 1.33%. Becton, Dickinson and’s dividend payout ratio (DPR) is 27.05%.
Several equities analysts recently weighed in on the stock. Morgan Stanley cut their price target on shares of Becton, Dickinson and from $285.00 to $270.00 and set an “equal weight” rating on the stock in a report on Thursday, August 27th. William Blair reaffirmed an “outperform” rating on shares of Becton, Dickinson and in a research note on Thursday, July 2nd. UBS Group raised their price objective on shares of Becton, Dickinson and from $265.00 to $280.00 and gave the stock a “neutral” rating in a research note on Monday, August 10th. TheStreet cut shares of Becton, Dickinson and from a “b” rating to a “c+” rating in a research note on Monday, September 21st. Finally, Goldman Sachs Group raised shares of Becton, Dickinson and from a “buy” rating to a “conviction-buy” rating in a research note on Friday, October 2nd. One analyst has rated the stock with a sell rating, seven have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $278.47.
About Becton, Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: What is a growth and income fund?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.